Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06761651Phase 1Recruiting

A Study of TAVO412 in Patients with Cancer (TAVO412)

Role: lead

NCT05298046Phase 1Completed

Study of TAVO101 in Healthy Volunteers

Role: lead

NCT06176040Phase 2Active Not Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Role: lead

NCT05548634Phase 1Active Not Recruiting

A Study of TAVO412 in Patients with Cancer

Role: lead

NCT05313152Phase 1Completed

Study of TAVO103A in Healthy Volunteers

Role: lead

All 5 trials loaded